Accelerator
Every published round Johnson & Johnson Innovation – JLABS took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Everyone Johnson & Johnson Innovation – JLABS has named to a program in published coverage. A place in a program is not a raise: the cheque is the figure recorded with the place, which is the program's standard terms where we hold them, and a blank is one we don't.
Companies Johnson & Johnson Innovation – JLABS has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Johnson & Johnson Innovation – JLABS, as distinct from the investments it has made.
Companies Johnson & Johnson Innovation – JLABS has backed that another company then bought. An exit for the holding, not a deal Johnson & Johnson Innovation – JLABS did.
Stories naming Johnson & Johnson Innovation – JLABS. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Antiviral nasal spray developer ENA Respiratory has joined the Blue Knight program run by JLABS and BARDA, the first Australian company selected; background notes recall its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.
Brandon Capital reports that ENA Respiratory has become the first Australian company chosen for BLUE KNIGHT, a JLABS-BARDA initiative supporting its intranasal broad-spectrum antiviral spray INNA-051.